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pancreatic carcinoma: a multicentre cohort study
Benjamin Kasenda1,2†, Annatina Bass1†, Dieter Koeberle3, Bernhard Pestalozzi4, Markus Borner5, Richard Herrmann1,
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Abstract
Background: Obesity is a risk factor for developing pancreatic cancer. We investigated the impact of obesity on
survival in patients diagnosed with locally advanced or metastatic pancreatic cancer.
Methods: In a multicentre, retrospective study, we included all patients with advanced or metastatic pancreatic
cancer treated at four Swiss hospitals between 1994 and 2004. We categorized patients into four body mass index
(BMI) groups (<18.5, 18.5 – 25, ≥ 25 – 29, ≥30 kg/m2) and used multivariable Cox regression to investigate the
impact of BMI on survival. Missing data were handled using multiple imputations.
Results: 483 patients were included. Median age was 66 years (range 59–74), 47% were female, 82% had stage IV
disease, 72% had an ECOG below 2, and 84% were treated with gemcitabine-based first-line chemotherapy. After a
median follow-up of 8.5 months, 6 and 12-month survival probabilities of the whole cohort were 67% (95% CI
63% - 71%) and 37% (95% CI 33% - 42%), respectively. Unadjusted 12-month survival rates in each BMI group were:
48% (95% CI 33% - 62%), 42% (95% CI 36% - 48%), 30% (95% CI 22% - 38%), and 11% (95% CI 4% - 24%), respectively.
In multivariable analysis, increasing BMI (HR 1.22, 95% CI 1.04 – 1.41, p = 0.012) and CA 19–9 (HR 1.07, 95% CI
1.02 – 1.11, p = 0.003) were significantly associated with worse survival prognosis. Patients with a good clinical
performance status (ECOG < 2) had a better prognosis (HR 0.76, 95% CI 0.65 – 0.96, p = 0.019).
Conclusions: Obese patients diagnosed with advanced pancreatic cancers have a worse prognosis compared to
non-obese patients. BMI should be considered for risk stratification in future clinical trials.
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Background
Advanced pancreatic adenocarcinoma is the fifth leading
cause of cancer-related deaths and carries a devastating
prognosis with 5-year survival rates of 6% [1,2]. Inci-
dence increases with age and most cases are diagnosed
above the age of 50 years at an unresectable stage of dis-
ease [3]. Obesity, smoking and dietary factors such as
red meat consumption are risk factors for developing
pancreatic cancer [4,5]. Moreover, physical activity seems
to decrease the risk of developing pancreatic cancer, espe-
cially among those who are overweight [6]. Underlying
mechanisms behind these associations are not fully eluci-
dated yet, but hyperinsulinaemia and insulin resistance are
considered key factors [7]. For patients with established
diagnosis of advanced pancreatic cancer only few prognos-
tic factors have been described. The most consistent one is
a reduced clinical performance status at the time of diag-
nosis, which is associated with decreased survival [8].
Recently high baseline serum concentration of the tumour
marker CA 19–9 has been identified as an independent
negative prognostic factor in two independent cohorts of
patients with advanced pancreatic cancer [8,9]. There is
some evidence that men have an increased risk of death
compared to women [9], however this association was not
confirmed by another group [10]. Obesity at the time of
diagnosis has been reported to be associated with worse
prognosis in several malignant diseases including prostate,
colon, and breast cancer [11-13] – an observation with
major implications given the epidemic prevalence of obesity
in many regions of the world. In the present study we
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investigated the impact of body mass index (BMI) on
survival in patients with advanced pancreatic carcinoma
accounting for known prognostic factors such as baseline
CA 19–9 concentration and clinical performance status.
Methods
Eligibility criteria and study design
All patients with stage III/IV pancreatic carcinoma treated
at four Swiss hospitals between 1994 and 2004 were
included, irrespective of age, PS, histopathological grade
or treatment modality. Patient data were retrospectively
collected using a pre-specified case report form that
recorded anonymized data about patient and tumour
characteristics at baseline, treatment, and follow-up. All
identified eligible patients from the participating centres
were included. Case report forms were checked for
consistency and queries re-checked with each centre be-
fore entering the data in a central database. The research
ethics committee of Basel (EKBB) approved this study.
Statistical considerations
We calculated overall survival (OS) from the time of
diagnosis until death due to any cause and estimated the
OS probabilities using the Kaplan-Meier method.
Follow-up was calculated for all patients irrespective of
survival status. We categorized BMI (body weight in
kilograms/[height in metres]2) according to four groups
(<18.5, 18.5 – 25, ≥ 25 – 29, and ≥ 30) as proposed by
the World Health Organization [14]. For illustration, we
plotted corresponding Kaplan Meier curves of each BMI
group. These unadjusted survival probabilities were
compared using the log-rank test; we also calculated un-
adjusted hazard ratios (HRs) with 95% confidence inter-
vals for these categories with BMI 18.5 – 25 as the
reference group. In an explorative unadjusted survival
analysis, we also investigated the association between in-
sulin and metformin intake on OS, respectively.
In our primary prognostic analysis, we investigated the
impact of BMI at time of diagnosis on OS using multivari-
able Cox regression analysis adjusted for the following
baseline characteristics: CA 19–9 serum concentration
(log transformed because of a very skewed distribution),
age (as continuous variable), sex, presence of diabetes,
performance status (Eastern Cooperative Oncology Group
[ECOG] <2 versus ECOG ≥ 2), and stage of disease (III
versus IV). In addition, we conducted one sensitivity ana-
lysis to investigate the robustness of the prognostic impact
of BMI. In this analysis, we only considered those patients
who received gemcitabine-based first-line therapy. Be-
cause BMI is an inherently continuous variable, in all
regression analyses, we included BMI as a continuous
variable as recommended [15] to circumvent the well-
known analytical pitfalls including loss of power and
spurious findings by arbitrarily choosing cut-offs or
categories [16]. For all survival analyses, missing data were
imputed using multiple imputations using chained equa-
tions [17,18]. In addition, we conducted bootstrap proce-
dures for internal model validation [19]. We present HR
and 95% confidence intervals from univariable analysis of
each risk factor, but irrespective of significance, they were
included in the multivariable analyses. The assumptions of
proportional hazards were investigated graphically and
tested using the Grambsch-Therneau test. P-value of < 0.05
(two-sided) was considered significant. We used the statis-
tical program STATA version 13.1 (STATA Corp, Texas,
USA) for analysis (see Additional file 1 for further details
about the statistical analyses).
Results
Patient characteristics
All 483 patients with advanced pancreatic cancer identi-
fied between 1994 and 2004 were included in our analyses;
characteristics are summarized in Table 1 stratified by
BMI group. The majority was diagnosed with stage IV dis-
ease; 41 patients (8.5%) were treated with best supportive
care only. The vast majority of patients underwent first-
line treatment with gemcitabine single agent (N = 286;
59%) or in combination with capecitabine (N = 65; 14%),
or cisplatin (N = 22; 5%) (Table 1). 186 (39%) patients
received a second line therapy after progression; 3rd, 4th,
and 5th line therapy was applied in 51 (11%), 13 (3%), and
3 (1%) patients, respectively.
Overall survival
After a median follow-up of 8.5 months (interquartile
range 2 – 15 months), 448 patients (93%) had deceased.
The respective 6, 12, and 24-month survival probabilities
for the whole cohort were 67% (95% CI, 63% - 71%),
37% (95% CI, 33% - 42%), and 11% (95% CI, 8% - 14%).
Figure 1 illustrates the OS probabilities grouped by the
four BMI groups following the WHO classification. The
unadjusted 12-month survival rates in each BMI group
were: 48% (95% CI 33% - 62%), 42% (95% CI 36% - 48%),
30% (95% CI 22% - 38%), and 11% (95% CI 4% - 24%), re-
spectively. The unadjusted HR for each BMI group was:
1.06 (95% CI 0.76 - 1.46, p-value = 0.748, BMI < 18.5), HR
1.00 (reference, BMI 18.5 – 25), 1.53 (95% CI 1.22 - 1.91,
p-value < 0.001, BMI ≥ 25 – 29), and 2.02 (95% CI 1.42 -
2.89, p-value < 0.001, BMI ≥ 30).
Primary prognostic analyses
Increasing BMI adversely affected survival; each increase in
5 units was independently associated with 21% relative risk
increase of death in our primary multivariable analysis (HR
1.21, 95% CI 1.06 – 1.41, p-value = 0.004). Patients with a
good clinical performance status (ECOG< 2) had a smaller
risk of death compared to patients with a worse perform-
ance status (HR 0.76, 95% CI 0.65 – 0.96, p-value = 0.019).
Kasenda et al. BMC Cancer 2014, 14:728 Page 2 of 7
http://www.biomedcentral.com/1471-2407/14/728
Increased CA 19–9 (on log scale) was significantly associ-
ated with decreased survival (1.07, 95% CI 1.02 – 1.11,
p-value = 0.003). Disease stage had no impact on survival
prognosis (Table 2). All findings were confirmed in the
internal model validation using bootstrap procedures. In
127 patients with known and treated diabetes at baseline,
insulin (treatment in 49/127 (38.6%) cases) or metformin
(treatment in 10/127 (7.9%) cases) had no impact on OS,
respectively (insulin, log-rank test p = 0.9687; metformin,
log-rank test p = 0.2023).
Sensitivity analyses
In the subpopulation of patients who received gem
citabine-based therapy (N = 407, Table 3) the prognostic
impact of BMI was little more pronounced with a 28% in-
crease of risk of death for each BMI increase by 5 units
(HR 1.31, 95% CI 1.10 - 1.50, p < 0.001). Disease stage also
had no impact on survival prognosis in this sensitivity
analysis. All results were confirmed by analyses based on
Table 1 Baseline characteristics of all included 483 patients with advanced pancreatic cancer
Characteristics
BMI < 18.5 BMI 18.5 - 25 BMI 25 - 30 BMI > =30 Total
N = 44 N = 294 N = 113 N = 32 N = 483
Age at diagnosis
Median(IQR) 64.3 (55.4, 73.6) 67.1 (58.9, 74.2) 66.6 (58.8, 74.1) 63.7 (58.2, 67.2) 66.4 (58.6, 74)
Sex
Female 24 (54.5) 135 (45.9) 36 (31.9) 13 (40.6) 208 (43.1)
Male 20 (45.5) 159 (54.1) 77 (68.1) 19 (59.4) 275 (56.9)
ECOG at diagnosis
ECOG > =2 9 (20.5) 64 (21.8) 27 (23.9) 5 (15.6) 105 (21.7)
ECOG < 2 35 (79.5) 230 (78.2) 86 (76.1) 27 (84.4) 378 (78.3)
Stage at diagnosis
III 8 (18.2) 58 (19.7) 22 (19.5) 3 (9.4) 91 (18.8)
IV 36 (81.8) 236 (80.3) 91 (80.5) 29 (90.6) 392 (81.2)
CA19-9 at diagnosis
Median (IQR) 392.1 (53.2, 2589.8) 546.1 (66.5, 3644) 801 (134.7, 4390) 689 (207.7, 14630.7) 609.6 (84.4, 3819.8)
Diabetes at diagnosis
Diabetes 10 (22.7) 74 (25.2) 29 (25.7) 14 (43.8) 127 (26.3)
No-diabetes 34 (77.3) 220 (74.8) 84 (74.3) 18 (56.2) 356 (73.7)
RTX at any therapy line
No-RTX 43 (97.7) 273 (92.9) 108 (95.6) 30 (93.8) 454 (94)
RTX 1 (2.3) 21 (7.1) 5 (4.4) 2 (6.2) 29 (6)
Most frequent 1st line chemotherapies
Gem 28 (63.6) 173 (58.5) 68 (60.2) 17 (53.1) 286 (59.2)
Gem + Cap 6 (13.6) 39 (13.3) 14 (12.4) 6 (18.8) 65 (13.5)
Gem + Cis 1 (2.3) 14 (4.8) 7 (6.2) 0 (0) 22 (4.6)
BSC 6 (13.6) 23 (7.8) 10 (8.8) 2 (6.2) 41 (8.5)
All values are numbers (percentages) unless otherwise specified. Median BMI was 23 (IQR 21–25). Abbreviations: BMI body mass index in kg / [height in m]2, BSC
best supportive care, Cap capecitabine, Cis cisplatin, ECOG PS Eastern Cooperative Group Performance Status, Gem gemcitabine, IQR inter quartile range,
RTX radiotherapy.
Figure 1 Overall survival by BMI group. Abbreviations: BMI = body
mass index; OS = overall survival.
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the bootstrap sample. In addition, male patients showed a
relative risk increase of 30% compared to women, how-
ever, this association was not consistent with our primary
analysis.
Discussion
Summary of findings
Overweight is associated with shortened survival in a co-
hort of European patients with advanced pancreatic cancer,
independently of known prognostic factors including high
CA 19–9 serum concentration at baseline, clinical per-
formance status and disease stage (III versus IV).
Strengths and limitations
Our data are based on a representative sample of patients
diagnosed and treated at four oncological centres in
Switzerland – one of the first cohorts of European patients
describing an association between BMI and prognosis. Fur-
thermore, our dataset allowed adjusting for baseline serum
CA 19–9 concentration, a recently recognized important
prognostic factor [8,9], clinical performance status, and
stage of disease. In addition, we report detailed information
on treatment regimens and investigated the independent
prognostic role of increased BMI also in the more
homogenous patient group treated with gemcitabine-based
first-line therapy – a valid standard treatment option,
Table 2 Primary prognostic analysis of mortality using multivariable Cox regression (N = 483)
Variable
Univariable Multivariable
HR 95% CI P-value HR 95% CI P-value
BMI
1.25 1.10 - 1.42 <0.001 1.21 1.06 - 1.41 0.004
(increments of 5 units)
Age (continuously) 1.00 0.99 - 1.00 0.865 1.00 0.99 - 1.01 0.920
Performance status
0.77 0.62 -0.97 0.024 0.76 0.65 - 0.96 0.019
(ECOG < 2 versus ECOG > =2)
Diabetes
0.94 0.76 -1.16 0.540 0.92 0.74 -1.14 0.438
(yes versus no)
Stage
0.84 0.65 -1.08 0.188 0.92 0.70 - 1.20 0.525
(stage III versus stage IV)
Sex
1.23 1.02 - 1.48 0.033 1.16 0.95 - 1.41 0.145
(male versus female)
CA 19-9
1.08 1.04 -1.13 <0.001 1.07 1.02 - 1.11 0.003
(continuously on log scale)
Abbreviations: BMI body mass index, CI confidence interval, ECOG Eastern Cooperative Oncology Group, HR hazard ratio.
Table 3 Sensitivity analysis of mortality using multivariable Cox regression techniques
Univariable Multivariable
Variable HR 95% CI P-value HR 95% CI P-value
BMI
1.30 1.13 - 1.48 <0.001 1.28 1.10. – 1.50 0.001
(in steps of 5)
Age (continuously) 1.00 0.99 - 1.01 0.695 1.00 0.99 - 1.01 0.405
Performance status
0.73 0.60 - 0.94 0.015 0.70 0.54 - 0.91 0.009
(ECOG < 2 versus ECOG≥ 2)
Diabetes
0.87 0.69 - 1.09 0.234 0.78 0.61 - 1.01 0.064
(yes versus no)
Stage
0.98 0.74 - 1.30 0.912 1.10 0.80 - 1.47 0.601
(stage III versus stage IV)
Sex
1.35 1.10 - 1.66 0.004 1.30 1.04 -1.63 0.023
(male versus female)
CA 19-9
1.08 1.04 - 1.12 <0.001 1.06 1.02 - 1.11 0.006
(continuously on log scale)
Only patients treated with gemcitabine-based first-line therapy were included (N = 407). Abbreviations: BMI body mass index, CI confidence interval, ECOG Eastern
Cooperative Oncology Group, HR hazard ratio.
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especially for elderly or frail patients [20]. Our results
proved robust in sensitivity analyses using bootstrap sam-
pling [19], a state of the art internal validation technique,
which further strengthens the evidence for BMI being an
independent prognostic factor.
Because of the retrospective design, several limitations
have to be addressed. First, in 29% BMI data were missing.
To circumvent the loss of power, risk of bias, and to use
all information available in the dataset for our analyses,
we used multiple imputations to impute missing values.
This approach has been proposed as a remedy for such
situations and its incorporation into routine practice has
been recommended to avoid biased estimates [17,21,22].
Also, the absolute number of obese and very obese
patients (BMI >30) in our Swiss cohort was much lower
(N = 32; 7%, Table 1) as compared to previously published
US cohorts [10]. Second, we had no data on the develop-
ment of BMI or onset of diabetes during therapy and
follow-up. Therefore we could not investigate whether
gain or loss of BMI would be of prognostic relevance over
time. This could be of interest, because loss of appetite
and weight are common problems during treatment of
patients suffering from advanced/metastatic pancreatic
cancer. Third, BMI as an indicator itself has some inher-
ent limitations: e.g. elderly patients tend to have a shift of
fat from peripheral to central sites with a concomitant
increase in waist-to-hip ratio [23] which is not reflected in
BMI. For such populations, and with evidence of health
risks associated with abdominal (visceral) fat, the waist-to-
hip ratio and waist circumference, have been commonly
used in epidemiological studies [23], but were not avail-
able in our dataset.
Compared to other studies
Our findings are in line with previous studies in cohorts
of US adults, which included a higher percentage of obese
(BMI ≥ 30) and very obese (BMI ≥ 35) patients and relied
on self-reported BMI data (weight and height) as opposed
to our measured data. In a Mayo Clinic cohort of patients
with all stages of pancreatic cancer, including patients with
early stage-disease who underwent surgery, Mc Williams
et al. report that BMI at diagnosis has a negative impact
on survival [10]. This was particularly pronounced in the
very obese patients with a BMI of 35 to 39.99 kg/m2 (HR
1.32, 95% CI 1.08-1.62) and > 40 kg/m2 (HR 1.60, 95% CI
1.26-2.04), respectively. However, this analysis did not
consider clinical performance status or CA 19–9 at base-
line. In a case–control study designed to assess the risk of
developing pancreatic cancer in overweight persons,
Li et al. describe a shorter survival for patients who were
overweight or obese during the year prior to diagnosis [4].
Based on 609 patients with all stages of pancreatic cancer
included in the survival analyses, the association between
obesity and overall survival was stronger among patients
with resected tumours (HR 3.35, 95% CI, 1.50 - 7.49) than
among those with unresected tumours (HR, 1.64, 95% CI
1.15 - 2.33). In patients with metastatic disease, obese pa-
tients (BMI ≥ 30) were at higher risk of death compared to
normal weight patients (HR 1.57, 95% CI 1.03 - 2.40) [4].
Interestingly in a recent report from the nurses’ health
study and the health professionals follow-up study [24],
higher pre-diagnosis BMI – as far as 20 years prior to
diagnosis – was also found to be associated with a shorter
time from diagnosis to death.
In our univariable prognostic analysis, there was a trend
towards better prognosis for patients with stage III disease
as compared to patients with stage IV disease (HR 0.84,
95% CI 0.65 - 1.08), however this association did not reach
the pre-defined level of statistical significance. Further-
more, in our primary multivariable analysis, this positive
effect was not confirmed at all (HR 0.92, 95% CI 0.70 -
1.20), suggesting that BMI, baseline CA 19–9, and ECOG
performance status are the most important prognostic
factors in advanced and metastatic pancreatic cancer.
Explanations for the association
Mechanisms behind the association between elevated BMI
and decreased survival are still unknown. Pancreatic can-
cer is a very rapidly progressing fatal malignancy, thus
most patients die because of uncontrollable disease.
Deaths due to comorbidities associated with obesity, such
as cardiovascular disease, are very unlikely to explain the
reduced overall survival. Chronic hyperinsulinaemia and
accompanying increased circulating C-peptide concentra-
tions have been suggested as a potential link between
obesity and the development of cancer in preclinical [25]
and epidemiological studies [26,27]. Consequently, we
hypothesize that the metabolic environment, in which the
cancer arises, might shape its biological behaviour and
therefore response to treatment and prognosis. However,
diabetes itself or diabetes treatment (insulin or metformin)
was not of prognostic value in our cohort.
On a practical level, under-dosing of chemotherapy in
obese patients may lead to decreased survival. Also, pa-
tients who were very obese received less second-line
chemotherapy in our cohort: Only 6 out of 17 (24%) very
obese patients (BMI ≥ 30) received at least one salvage
therapy after first-line palliative therapy which was less
compared to patients from lower BMI groups (<18.5, 10/31
[32%]; 18.5 – 25, 69/211 [33%]; ≥ 25 – 29, 27/75 [36%]).
One could assume that patients with very low BMI (<18.5)
would also have a worse survival prognosis, because very
low BMI may indicate higher frailty and malnutrition at
diagnosis. In fact, epidemiological studies on healthy
Caucasian individuals show that the association between
BMI and all cause mortality is best described by a J-shaped
curve [28]. However, similar to another US study [10], in
our analysis there was no difference between patients from
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the lowest BMI group (BMI < 18.5) compared to normal
weight patients (BMI 18.5 – 25.0). Given the relatively small
sample size (BMI < 18.5, N = 44), one can still assume that
this possible association just did not become evident be-
cause of limited statistical power. In addition, around 80%
of patient with BMI < 18.5 had a good clinical performance
status and we cannot rule out that patients with worse per-
formance status never presented to one of the participating
centers.
Implications for clinical practice and further research
Results from our study and others suggest that metabolic
factors associated with obesity play a central role in the
development and progression of pancreatic cancer. An
immediate implication for clinical researchers is to include
obesity (e.g. BMI ≥30) as a stratification variable in ran-
domized clinical trials for patients with pancreatic cancer.
Furthermore, drug dosing and distribution in the rapidly
growing population of obese and very obese patients
deserves further systematic investigations. Molecular
characterization of malignant disease in the chronically
overweight will reveal whether cancer that has arisen in
the metabolic environment of obese patients is indeed a
different disease. Finally, further research is needed to as-
sess whether changes in body weight, e.g. through exercise
interventions, with increase in lean body mass and/or de-
crease in adipose tissue alters not only some quality of life
items [29] but also response to treatment and prognosis.
Conclusion
Overweight patients with advanced or metastatic pancre-
atic carcinoma have a shortened survival compared to nor-
mal weight patients. Mechanisms explaining the
association between increased BMI and worse prognosis
are still not fully understood. However, because BMI is
such a simple clinical marker, its strong prognostic value in
patients with pancreatic cancer should be considered for
risk stratification in future trials.
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